prostate cancer - search results
If you're not happy with the results, please do another search
Researchers Detail Clues to Prostate Cancer Therapy Resistance, ID New Treatment Strategy
This study revealed that antiandrogen therapy induces viral mimicry responses that are crucial for antitumor activity.
Genetic PSA Score May Improve Prostate Cancer Screening Accuracy
Incorporating genetic factors that influence prostate-specific antigen (PSA) level into prostate cancer screening may help reduce unnecessary invasive testing and improve the detection of aggressive disease.
Potential Approach for Prostate Cancer Treatment Uncovered
Researchers at CAS Center for Excellence in Molecular Cell Science of the Chinese Academy of Sciences demonstrated in mouse models the oncometabolite role of progesterone in advanced prostate cancer and strategies to eliminate its oncogenic effect.
Prostate Cancer and Treatment Differs in Black Men
Black men with prostate cancer may respond well to androgen deprivation therapy (ADT)-based regimens, but they are less likely to receive such therapy than non-Blacks, according to a new multi-institutional retrospective analysis.
Hormone-Sensitive Prostate Cancer Patients Survival Improved with Combination Therapy
A Phase III clinical trial led by scientists at Massachusetts General Hospital showed that adding darolutamide to androgen-deprivation therapy and chemotherapy extended the survival of men with metastatic, hormone-sensitive prostate cancer.
Prostate Cancer Similarities Between Man and Dog Helps ID New Drug Target
In a first-of-its-kind study on dogs with naturally occurring prostate cancer, scientists have discovered that blocking CCR4 expressing regulatory T cells that infiltrate tumors and prevent other immune cells from annihilating tumor cells, may be a promising therapeutic strategy for advanced prostate cancer in dogs and a subset of human patients.
Optimal High-Risk Prostate Cancer ADT Duration May Be Radiotherapy-Dependent
The analysis, which combined individual patient data from three different cohorts, showed that men receiving high-dose external beam radiotherapy (EBRT) alone may benefit from at least 18 months of ADT whereas those who receive EBRT plus a brachytherapy boost may be optimally managed with 18 months of ADT or less.
Open Data Collaboration Shows AI Can Accurately Diagnose Prostate Cancer
A large study led by the Karolinska Institute in Sweden shows that artificial intelligence can be used to accurately diagnose and grade prostate cancer in a way that is generalizable across different populations.
23andMe Launches First Cancer Drug Trial and Gets FDA Nod for Prostate Cancer Marker
The launch of the clinical trial wholly sponsored by 23andMe is a pivotal achievement for the company’s therapeutic development division, which was started in 2015. But in 2020 GSK launched a trial of a drug candidate that came out of its collaboration with 23andMe, which started in 2018.
Black Prostate Cancer Patients’ Radiation Therapy Outcomes Better Even with Higher Risk Disease
A meta-analysis of radiation therapy trials by UCLA Jonsson Comprehensive Cancer Center researchers showed that black men with more aggressive disease appeared to have better outcomes than their white counterparts.